Eli Lilly and Company (LLY)
| Market Cap | 780.72B |
| Revenue (ttm) | 45.04B |
| Net Income (ttm) | 10.59B |
| Shares Out | 900.43M |
| EPS (ttm) | 11.71 |
| PE Ratio | 74.04 |
| Forward PE | 37.51 |
| Dividend | $6.00 (0.69%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 2,524,566 |
| Open | 857.18 |
| Previous Close | 857.20 |
| Day's Range | 857.18 - 881.33 |
| 52-Week Range | 711.40 - 972.53 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 985.00 (+13.6%) |
| Earnings Date | Feb 6, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the comp... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $985.0, which is an increase of 13.60% from the latest price.
News
Lilly to participate in TD Cowen's 45th Annual Health Care Conference
INDIANAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice pres...
Top 5 growth stocks to watch in 2025 as market momentum builds
While concerns about a potential US recession persist, growth stocks have continued to outperform value stocks in 2024. Investors remain optimistic that the Federal Reserve's expected interest rate cu...
Calls of the Day: Live Nation, Eli Lilly, AT&T, Adobe and Astera Labs
The Investment Committee discuss the latest Calls of the Day.
Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs
SAN DIEGO--(BUSINESS WIRE)--Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacemen...
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
BRISBANE, Australia & INDIANAPOLIS--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and bre...
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
SEONGNAM, South Korea--(BUSINESS WIRE)-- #CardiometabolicIndications--OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX's OLX75016.
23 Upcoming Dividend Increases, Including 2 Kings
Excited to announce dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Companies with consistent dividend growth indica...
Buy, Sell, Or Hold LLY Stock At $870?
Eli Lilly (NYSE: LLY) fourth-quarter performance exceeded the street expectations, with the company delivering adjusted earnings of $5.32 per share versus the projected $4.95. Revenue came in at $13.5...
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one ye...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America's health focus across obesity and be...
Eli Lilly climbs after earnings, top analyst talks what's next for pharma giant
David Risinger, Leerink Partners, joins 'Fast Money' to talk Eli Lilly earnings.
Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight
Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year. Tirzepatide, marketed as M...
Eli Lilly and Company (LLY) Q4 2024 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY) Q4 2024 Results Conference Call February 6, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations David Ricks - Chair and CE...
Why did Eli Lilly report mixed Q4 results despite soaring demand for Zepbound and Mounjaro?
Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and diab...
Eli Lilly Stock Rises After Profit, Outlook Top Expectations
Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.
LLY Gains on Weight Loss Drugs, F Tariff Fears, HON Split
Eli Lilly (LLY) shares ran higher following its earnings report with its weight loss drugs in focus. Ford Motor Co. (F) hit a 52-week low with tariffs from President Trump posing questions around the ...
Novo, Lilly still leaders in obesity drug development: Barclays
Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity drug market.
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
On Thursday, Eli Lilly and Co LLY stock is trading higher after the company released better-than-expected fourth-quarter earnings and provided 2025 guidance.
Lilly says Mounjaro and Zepbound contributed to big revenue boost
Lilly's CEO says that the company has “tremendous momentum” entering 2025.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company expects...
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates.
Eli Lilly posts mixed quarter even as demand for weight loss - diabetes drugs soars
CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.
Eli Lilly Stock Rises After Earnings Beat
Fourth-quarter adjusted earnings of $5.32 a share beat analysts' estimates of $5.01.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but saw lower realized prices. Demand in the U.S. has far outpaced supply for ...